Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9

Figure 1 Beeswarm scatter plot of PC-594 levels in control and pancreatic cancer patient sera. Boxes indicate the 25^th to 75^th percentile, while the horizontal line in the box represents the median level. Whiskers indicate the 5^th to 95^th percentile.

Figure 2 Receiver-operator characteristic analysis of PC-594. A: ROC curve based on PC-594 levels in PaC and control subjects, Dotted lines indicate the 95%CI; B: Line pots of sensitivity and specificity vs serum PC-594 concentration.

Figure 3 Beeswarm scatter plot of PC-594 levels by disease stage (A) and gender (B). Boxes indicate the 25^th to 75^th percentile, while the horizontal line in the box represents the median level. Whiskers indicate the 5^th to 95^th percentile. PaC: Pancreatic cancer.

Figure 4 Age analysis. Scatter plots of PC-594 level vs age for controls (A) and PaC patients (B); Beeswarm scatter plot of PC-594 levels by age in controls and PaC patients (C). Boxes indicate the 25^th to 75^th percentile, while the horizontal line in the box represents the median level. Whiskers indicate the 5^th to 95^th percentile.

Figure 5 CA19-9 levels. A: Beeswarm scatter plot of CA19-9 levels in controls and PaC patients. Grey lines indicate median levels; B: ROC curve based on CA19-9 levels; Dotted lines indicate the 95%CI.

Figure 6 Correlation between CA19-9 and PC-594. Scatter plots of PC-594 vs CA19-9 concentrations (A, log10; B, unlogged). In B, the dotted box A represents CA19-9 above 35 U/mL and PC-594 levels above 1.25 (elevated CA19-9 and normal PC-594), while the dotted box B represents CA19-9 levels below 35 U/mL and PC-594 levels below 1.25 (normal CA19-9 and abnormal PC-594).